Gemzar®(Ci) and epirubicin (E) in patients (pts) with metastatic breast cancer(MBC):: Final results of a phase I dose finding study

被引：0
|
作者：
Fumoleau, P
Viens, P
Dieras, V
Pujade-Lauraine, E
Espie, M
Kayitalire, L
Rongier, AM
Pouillart, P
机构：
[1] Ctr Rene Gauducheau, F-44035 Nantes, France
[2] Inst J Paoli I Calmettes, F-13009 Marseille, France
[3] Inst Curie, Paris, France
[4] Hop St Louis, Paris, France
[5] Hotel Dieu, Paris, France
来源：
EUROPEAN JOURNAL OF CANCER | 1999年 / 35卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1173
引用
收藏
页码：S292 / S292
页数：1
相关论文
共 50 条
  • [21] Navelbine (NVB) alternating oral and i.v. plus epirubicin (EPI) as first line chemotherapy of metastatic breast cancer (MBC): phase II study - final results
    Serin, D.
    Verrill, M.
    Jones, A.
    Delozier, T.
    Coleman, R.
    Longerey, B.
    de Micheaux, S. Lafaye
    EJC SUPPLEMENTS, 2004, 2 (03): : 130 - 131
  • [22] Phase I trial of pegylated liposomal doxorubicin and lapatinib in the treatment of metastatic breast cancer (MBC): Final results
    Cianfrocca, Mary E.
    Kaklamani, Virginia G.
    Rosen, Steven T.
    Von Roenn, Jamie H.
    Rademaker, Alfred
    Smith, Deborah A.
    Rubin, Stephen D.
    Meservey, Caitlin
    Uthe, Regina
    Gradishar, William John
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [23] Weekly paclitaxel (TAX) and capecitabine (CAP) for metastatic breast cancer (MBC) patients (PTS) previously treated with anthracycline-containing therapy: A phase I dose-finding study.
    Susnjar, S
    Bosnjak, S
    Radulovic, S
    Stevanovic, J
    Gajic-Dobrosavljevic, M
    Kreacic, M
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 90S - 90S
  • [24] A phase II study of HER3-DXD in patients (pts) with metastatic breast cancer (MBC)
    Hamilton, E. P.
    Bagegni, N. A.
    Beck, J. T.
    Cultrera, J. L.
    Dosunmu, O.
    Gwin, W. R.
    Heeke, A. L.
    Khoury, K.
    Sellami, D.
    Shastry, M.
    Sternberg, D. W.
    Toppmeyer, D.
    Wright-Browne, V. M.
    Yuan, Y.
    ANNALS OF ONCOLOGY, 2022, 33 : S220 - S220
  • [25] A phase 2 study of HER3-DXd in patients (pts) with metastatic breast cancer (MBC)
    Hamilton, Erika P.
    Dosunmu, Ololade
    Shastry, Mythili
    Finney, Lindsey
    Sellami, Dalila B.
    Sternberg, David W.
    Wright-Browne, Vance
    Toppmeyer, Deborah
    Gwin, William R.
    Thaddeus, J. Thaddeus
    Cultrera, Jennifer L.
    Bagegni, Nusayba Ali
    Khoury, Katia
    Heeke, Arielle Lutterman
    Yuan, Yuan
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [26] A phase I dose-finding trial of UFT/leucovorin (LV) in combination with vinorelbine (VNB) in patients with metastatic breast cancer (MBC).
    Fumoleau, P
    Bonneterre, J
    Kerbrat, P
    Fargeot, P
    Déporte-Féty, R
    Garet, F
    ANNALS OF ONCOLOGY, 2000, 11 : 32 - 33
  • [27] Phase Ib study of ixabepilone (I) in combination with epirubicin (E) in women with metastatic breast cancer
    Roche, H. H.
    Zambetti, M.
    Dalenc, F.
    Govi, S.
    Gladieff, L.
    Mudenda, B.
    Lainas, I.
    Iacono, L.
    Gianni, L.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [28] Interim safety results of eribulin (E) combined with ramucirumab (RAM) in patients (pts) with advanced metastatic breast cancer (MBC)
    Yardley, Denise Aysel
    Osborne, Cynthia R. C.
    Richards, Paul D.
    Daniel, Brooke R.
    Danso, Michael A.
    Favret, Anne
    Bromund, Jane
    Hsu, Yanzhi
    Ibrahim, Ayman B.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (27)
  • [29] A phase I dose finding study of E7080 in patients (pts) with advanced malignancies
    Glen, H.
    Boss, D.
    Evans, T. R.
    Roelvink, M.
    Saro, J. M.
    Bezodis, P.
    Copalu, W.
    Das, A.
    Crosswell, G.
    Schellens, J. H.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [30] High dose chemotherapy (HDCT) and hematopoietic stem cell transplantation (HPSCT) with subsequent immunotherapy in metastatic breast cancer (MBC): Final results of a phase I study.
    Stemmler, HJ
    Salat, C
    Lindhofer, H
    Menzel, M
    Sauer, H
    Untch, M
    Konecny, G
    Ledderose, G
    Kolb, HJ
    Heinemann, V
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 58S - 58S
12345